pp-024 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Indication: Thyroid-associated eye disease (TED) related to Graves’ disease (GD), Phase I. Long-acting monoclonal antibody targeting the TSH receptor pathway; extended-half-life formulation; best-in-class (BIC) potential and positioned as a globally leading next-generation therapy. Route / form: Subcutaneous injection.
Manufacturer #7041
This pioneering genetic-engineering–based pharmaceutical company is known for its advances in child and women’s health, supported by nearly three decades of experience in biopharmaceuticals and innovative drug development. It operates tech-driven R&D platforms with over 80 pipeline projects and more than 120 marketed products. The organization is expanding into additional high-need therapeutic areas, including endocrinology, immunology and oncology, while actively pursuing global innovation and commercial partnerships.
Manufacturer usually replies in 74 days